TerminatedPhase 1NCT01791686
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Studying C3 glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celldex Therapeutics
- Principal Investigator
- Carla Nester, MD, MSAUniversity of Iowa
- Intervention
- CDX-1135(drug)
- Enrollment
- 1 enrolled
- Eligibility
- 4 years · All sexes
- Timeline
- 2013 – 2014
Study locations (1)
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01791686 on ClinicalTrials.govOther trials for C3 glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06209736Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNOmeros Corporation
- ACTIVE NOT RECRUITINGPHASE3NCT05809531An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisApellis Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT04183101Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyRegion Skane
- RECRUITINGPHASE3NCT03955445Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNNovartis Pharmaceuticals